Epstein-Barr virus nuclear antigen 1 peptide–major histocompatibility complex (EBNA1-pMHC)

The Epstein-Barr virus nuclear antigen 1 (EBNA1) peptide–major histocompatibility complex (MHC) is a specialized molecular target presented on the surface of cells infected with the Epstein-Barr virus (EBV). EBNA1 is a multifunctional viral protein required for the replication and persistence of the EBV episome during the latent phase of infection (UniProt P03211). It is uniquely significant because it is the only viral protein expressed in all EBV-associated malignancies, including Nasopharyngeal Carcinoma, Burkitt Lymphoma, and Post-Transplant Lymphoproliferative Disorder (PTLD), making it a universal marker for EBV-positive tumors (Longnecker et al., 2013). The complex is formed when EBNA1 is processed into short peptides and presented by MHC molecules (typically HLA-A*02:01 or other Class I/II alleles) to the immune system. Therapeutic strategies targeting this complex include adoptive T-cell therapies, such as Tabelecleucel, and experimental T-cell receptor (TCR)-like antibodies that recognize the specific peptide-MHC configuration with high affinity (Tang et al., 2022). These therapies aim to selectively eliminate EBV-infected cells while avoiding healthy tissue, though challenges remain regarding viral immune evasion through the inhibition of proteasomal processing and HLA downregulation (Levitskaya et al., 1995).

Other names

EBNA1-HLA complexEBNA1 peptide-MHCEpstein-Barr virus nuclear antigen 1-MHC complexEBNA1-pMHC

T-cell receptor (TCR) mediated cytotoxicity, Antibody-dependent cellular cytotoxicity (ADCC), and targeted cell lysis via recognition of the peptide-MHC complex.